The OIS Index Consists of Publicly Traded Growth Companies in Ophthalmology

Powered By:

We introduced the OIS Index, a composite of ophthalmic growth stocks, in October 2016 at OIS@AAO with the purpose of tracking the performance of our sector. The components of the OIS Index are publicly traded growth companies in ophthalmology that derive at least half of their value from ophthalmic products and technology. The index was launched with a base value of 1,000. The index is weighted about 50% biopharma and 50% ophthalmic device, based on company valuations. Company market caps range from $30 million to $30 billion, with a median of $200 million.

OIS Index

September 1, 2020


Index Performance (% Chg.)1 Month3 Months1 Year
OIS Index (OIS)-0.4%-5.0%-1.8%
NASDAQ Biotechnology Index (NBI)0.9%0.8%31.8%
US Medical Device Index (IHI)3.7%13.2%21.9%
US Market: Russell 3000 Index (R3000)7.1%15.5%19.2%

OIS Index - Three Month Performance

May 29, 2020 - August 31, 2020

Index values are scaled to 100 as of the initial date in the chart.

OIS Index - One Year Performance

August 30, 2019 - August 31, 2020

Index values are scaled to 100 as of the initial date in the chart.

OIS Index Components

Adverum Biotechnologies Inc.
Aerie Pharmaceuticals Inc.
Aerpio Pharmaceuticals
Aldeyra Therapeutics Inc.
Alimera Sciences Inc.
Apellis Pharmaceuticals, Inc.
Applied Genetic Technologies Corp.
Bausch Health
Carl Zeiss Meditec AG
Clearside Biomedical, Inc.
EyeGate Pharma
EyePoint Pharmaceuticals
GenSight Biologics SA
Glaukos Corp.
Harrow Health
Iridex Corp.
Kala Pharmaceuticals
KalVista Pharmaceuticals Ltd.
Molecular Partners AG
Nicox SA
Ocular Therapeutix Inc.
Omeros Corp.
Opthea Ltd.
Oyster Point Pharmaceuticals
Santen Pharmaceutical
Second Sight Medical Products Inc.
STAAR Surgical Co.
The Cooper Companies, Inc.
UNITY Biotechnology